^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RAV 12

    i
    Other names: RAV12, anti-RAAG12 mAb, RAV 12
    Associations

    News

    Trials
    Company:
    MacroGenics
    Drug class:
    Tumor-associated antigen inhibitor
    Related drugs:
    Associations

    News

    Trials
    almost4years
    [VIRTUAL] THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES (EBMT 2020)
    Additionally, for TCRalpha-chain expression these populations used either TRAV12 or TRAV30... In conclusion, we isolated and validated the first functional HLA-A*01:01-restricted EBV-LMP2-specific T-cell populations and TCRs, which can be used for adoptive transfer or retro/lentiviral TCR gene therapy to treat EBV-associated type II/III lymphomas, EBV+ malignancies of epithelial origin and PTLDs.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    RAV 12
    almost4years
    [VIRTUAL] THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES (EBMT 2020)
    Additionally, for TCRalpha-chain expression these populations used either TRAV12 or TRAV30... In conclusion, we isolated and validated the first functional HLA-A*01:01-restricted EBV-LMP2-specific T-cell populations and TCRs, which can be used for adoptive transfer or retro/lentiviral TCR gene therapy to treat EBV-associated type II/III lymphomas, EBV+ malignancies of epithelial origin and PTLDs.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    RAV 12
    almost4years
    [VIRTUAL] THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES (EBMT 2020)
    Additionally, for TCRalpha-chain expression these populations used either TRAV12 or TRAV30... In conclusion, we isolated and validated the first functional HLA-A*01:01-restricted EBV-LMP2-specific T-cell populations and TCRs, which can be used for adoptive transfer or retro/lentiviral TCR gene therapy to treat EBV-associated type II/III lymphomas, EBV+ malignancies of epithelial origin and PTLDs.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    RAV 12
    over4years
    [VIRTUAL] THE FIRST FUNCTIONAL HLA-A*01:01-RESTRICTED EBV-LMP2-SPECIFIC T-CELL RECEPTORS FOR TCR GENE THERAPY OF PATIENTS WITH EBV-ASSOCIATED TYPE II/III MALIGNANCIES (EBMT 2020)
    Additionally, for TCRalpha-chain expression these populations used either TRAV12 or TRAV30... In conclusion, we isolated and validated the first functional HLA-A*01:01-restricted EBV-LMP2-specific T-cell populations and TCRs, which can be used for adoptive transfer or retro/lentiviral TCR gene therapy to treat EBV-associated type II/III lymphomas, EBV+ malignancies of epithelial origin and PTLDs.
    Clinical • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    RAV 12